mouse monoclonal IgG2a; p18 INK4C Antibody (118.2) is an IgG2a κ mouse monoclonal p18 INK4C antibody (also designated CDKN2C antibody, p18 antibody, CDKN6 antibody or p18-INK4c antibody) that detects the p18 INK4C protein of mouse, rat and human origin by WB, IF, IHC(P) and ELISA. p18 INK4C Antibody (118.2) is available as both the non-conjugated anti-p18 INK4C antibody form, as well as multiple conjugated forms of anti-p18 INK4C antibody, including agarose, HRP, PE, FITC and multiple Alexa Fluor® conjugates. The normal progression of cells through the cell cycle is under the control of the cyclin dependent protein kinases Cdk4 and Cdk6, which are subject to inhibition by the mitotic inhibitory protein p16 INK4A. Isolated members of the p16 INK4A family have been designated p15 INK4B and p18 INK4C. p15 INK4B expression is upregulated approximately 30-fold in TGFβ-treated human keratinocytes. The gene encoding p15 INK4B has been mapped to chromosome 9p21.3 at a position adjacent to the p16 INK4A gene, at a site of frequent chromosomal abnormality in human tumors. It has been suggested that p15 may function as an effector of TGFβ-mediated cell cycle arrest through inhibition of Cdk4 and Cdk6 kinase. The second p16-related protein, p18 INK4C, interacts strongly with Cdk6 and to a lesser extent with Cdk4, but lacks apparent interaction with other Cdks. Recombinant p18 INK4C has been shown to inhibit cyclin D-Cdk6 kinase activity. In contrast to p21 Waf1/Cip1/p27 that form ternary complexes with cyclin-Cdks, only binary complexes of p15 INK4B, p16 INK4A and p18 INK4C have been identified in association with Cdk4 and/or Cdk6.